Gyros AB Platform Chosen by EMD Millipore in Expansion of Contract Service Offerings
“As a contract service organization to pharma, our reputation is founded on quality, reliability and cost-effectiveness," said Christina Shasserre, Head of Discovery and Development Solutions for EMD Millipore. “To this end, we are continually looking for solutions that enhance our throughput and output to exceed our customers' expectations. The Gyrolab workstation is an integral part of this equation.”
"In our evaluation of the Gyrolab xP workstation, we were particularly impressed with the system’s high level of accuracy; rapid method development and validation; and delivery of robust assays—even in 50% matrix," said Ron Bowsher, Chief Scientist for BioPharma Services at EMD Millipore. “Incorporating Gyrolab technology into our offering will give us a competitive advantage for servicing the fields of pharmacokinetics, anti-drug antibody, and host-cell protein (HCP) testing.”
Commenting on the announcement, Erik Walldén, CEO at Gyros, said: “We see EMD Millipore’s investment as strong confirmation that our offering delivers what is important to our customers. From a company perspective, this signals a growing acceptance of our technology, and a major step in our expansion, within the US market.”
Enquiries: Lorna Cuddon Zyme Communications Ltd Tel: +44 (0) 7811 996 942 Skype: lorna.cuddon Email: lorna.cuddon@zymecommunications.com
About Gyros AB http://www.gyros.com
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.
About EMD Millipore www.millipore.com
EMD Millipore is the Life Science division of Merck KGaA* of Germany and offers a broad range of innovative performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 64 countries and pro forma 2009 revenues of $2.9 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.
*Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany
For further information about EMD Millipore, please contact: Christina Shasserre, Head of Discovery and Development Solutions Tel: +1-636-685-5082 christina.shasserre@emdchemicals.com
Greg Hoff, Media Relations Manager Tel. +1-978-762-5170 greg_hoff@millipore.com
Gyros, Gyrolab and the Gyros logo are trademarks of Gyros Group. Millipore is a registered trademark of Millipore Corporation. EMD is a registered trademark of Merck KGaA.